Innovations of Drug Design and Development - SHB4018

Assessment 1: Written assignment (coursework)

The formative assessment will be similar in learning outcomes and problem-solving tasks to those required in the summative report, as outlined below.

Written assignment

Assessment 2: Exam

Exam

Assessment 1: Written Assignment

A case study on the design, testing and clinical evaluation of a drug(s) from first principles, with consideration given towards pharmacogenetic and pharmacogenomics factors.

<p>This module provides a detailed investigation of all the stages of drug development. The module begins with drug design and methods of discovery (chemical synthetic, biotechnological, animal and plant origin). The fundamentals of the pre-clinical, clinical trials and monitoring of new drugs will be covered, outlining the required stages and difficulties of introducing new drugs.  The drug development process will be extended to an appreciation of how genetic variation may underpin personalized medicine, especially in the context of pharmacogenomic analysis. Biomarkers are used as surrogates for genotypic direction of personalized medicine and the science of these developments will be considered in detail. The pharmacodynamic and pharmacokinetic perspectives will be studied as well as inter-patient variation in the expression of drug metabolising/ activating enzymes and differences in expression of drug targets such as receptors, genes, enzymes and growth factors. bioinformatics and the relevant IT will be explored in relation to ‘OMIC’ technologies as applied to pharmacogenomics. </p>

School of Applied Sciences

<p><a href="https://library.hud.ac.uk/readinglists/SHB4018">https://library.hud.ac.uk/readinglists/SHB4018</a></p>

Container 1

Biomedical & Life Sciences

SHB4018 - Innovations of Drug Design and Development

Innovations of Drug Design and Development

Critically appraise specific drugs in terms of their capacity for inter and intra-patient variation.

Apply pharmacogenetic and pharmacogenomic principles to therapeutic manoeuvres.

Understand how pharmacogenetic and pharmacogenomic studies may lead to personalized medicine, including clinical trials.  

Demonstrate a critical awareness and in-depth appreciation of drug development.

Be aware of the uses and limitations of bioinformatic technologies on the validation of biomarkers, drug targets and personalised medicine.

Explain how a drug’s chemical and structural properties can be used to predict its efficacy and potency, lability and stability and genotypic targeting in vivo.

Understand how ‘omic’ and bioinformatic technology may be applied to drug design, development, monitoring and application.